About Us
King, an S&P 500 Index company, is a vertically integrated branded pharmaceutical company that develops, manufactures and markets therapies and technologies primarily in specialty-driven markets including neuroscience, hospital and acute care medicines.
King’s business model offers the best qualities of a big and small company in one fully integrated pharmaceutical company. Our size enables us to build close personal relationships with the medical community and flexible collaborative partnerships with other pharmaceutical companies. Fully integrated resources in scientific and technical operations, coupled with a fully aligned sales force, enable us to move quickly to capitalize on scientific advances and bring innovative medicines and technologies to market. These strategic competencies, combined with dynamic executive leadership, strategic discipline and financial strength, have established King as a leading specialty pharmaceutical company.
Sales and Marketing
As the company has grown, so have its marketing capabilities. Today, we market our Branded Prescription Pharmaceutical Products primarily through a dedicated sales force of over 700 individuals through out the U.S., Canada and Puerto Rico. Our Animal Health Products are marketed primarily through a dedicated sales force of approximately 100 individuals in the U.S, Europe, Canada, Latin America and Asia.
Research and Development
King’s highly cost-effective, readily scalable R&D model sets it apart from other pharmaceutical companies. Its 100-person strong in-house R&D team includes drug development scientists, regulatory and drug safety staff, who manage the full range of R&D activities for late-stage products: drug discovery, clinical development, drug safety, regulatory affairs, medical affairs and project management.
Manufacturing
King currently operates manufacturing facilities – in Bristol, Tennessee; Rochester, Michigan; St. Louis, Missouri; St. Petersburg, Florida; and Middleton, Wisconsin – that produce a broad array of dosage forms, including tablets, capsules, liquids, suspensions, solutions, suppositories, creams, ointments, injectables, auto-injector products and other drug products. In addition, King’s Alpharma Animal Health Division operates manufacturing facilities in Chicago Heights, Illinois; Longmont, Colorado; Salisbury, Maryland; Willow Island, West Virginia; Van Buren, Arkansas; Shenzhou, China; and Yantai, China.
Financial Highlights
King’s revenues have grown from $13 million in 1994 to over $1.5 billion in 2008. King’s common stock trades on the New York Stock Exchange under the symbol “KG,” and is a component of the S&P 500 Index and the AMEX pharmaceutical index.
Relying on talented and dedicated employees, following a strategic vision and developing trusted relationships with other drug companies, wholesalers, physicians and pharmacists, King is redefining the standards for success in pursuing opportunities in the health care industry.
About Forward-Looking Statements
The foregoing contains forward-looking statements, which reflect management’s current views of future events and operations, including, but not limited to, statements pertaining to King’s future growth. These forward-looking statements involve certain significant risks and uncertainties, and actual results may differ materially from the forward-looking statements. Some important factors, which may cause results to differ include those discussed in the “Risk Factors” section and other sections of King’s Form 10-K for the year ended December 31, 2008, which is on file with the Securities and Exchange Commission. To view risk factors pertaining to forward-looking statements, click on the following link: Risk Factors. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.
